Management of Chronic Hepatitis and Copper Accumulation with Ayurveda – A Single Case Study

Authors

  • ANKITA PRAHALADBHAI PATEL M.D (Ayu) Kaumarbhritya, Assistant Professor, Department of Ayureda, Ananya Ayurved college, Gujarat, India.
  • Das Ashok kumar Nathulal
  • Haresh Vyas

Keywords:

Hepatitis, Hepatic encephalopathy, Copper IC-PMS, Tapyadi Loha, Phalatrikadi Kwath.

Abstract

Hepatitis is a general term can be define as inflammation of the liver caused due to several factors such as viruses, chemicals, drugs, alcohol
and certain genetic disorders or by an overactive immune system which mistakenly attacks the liver known as autoimmune hepatitis. Hepatitis can be acute, which appears immediately and goes away quickly, or chronic, which is a long-term condition that typically produces more mild symptoms and gradually damages the liver. A patient suffered from recurrent hepatitis, one episode of hepatic encephalopathy for 4 year and with high copper
IC-PMS value given Ayurvedic medicine Tapyadi Loha, Phalatrikadi Kwath and Pipala Patra with  Guda, by that patient was benefited in symptomatic complaints with normal USG reports and normal copper IC-PMS value within 2 year. The present case study focuses on whether chronic hepatitis can be successfully treated with formulations mentioned in Ayurveda due to drugs mainly acts as Pittavirechaka, Shothahara, Yakruduttejaka Rasayana and Dhatuvardhaka which helps in improving the functioning of liver.

References

Marsh K, Tayler R, Pollock L, Roy K, Lakha F, Ho A, Henderson D, Divala T, Currie S, Yirrell D, Lockhar M, Rossi MK, Phin N. Investigation into cases of hepatitis of unknown aetiology among young children, Scotland, 1 January 2022 to 12 April 2022. Euro Surveill. 2022; 27(15): 2200318.DOI:10.2807/15607917.ES.2022.27.15.2200318 - DOI - PMC – PubMed (accessed on 2023 March 5).

Brennan PN, Donnelly MC, Simpson KJ. Systematic review: non A-E, seronegative or indeterminate hepatitis; what is this deadly disease?Aliment Pharmacol Ther. 2018; 47(8): 1079–1091p. DOI:10.1111/apt.14566 - DOI - PubMed (accessed on 2023 March 5).

Zhou Z, Xu MJ, Gao B. Hepatocytes: a key cell type for innate immunity. Cellular & Molecular Immunology. 2016; 13(3): 301–315p.

Wu F, Wang J, Pu C, Qiao L, Jiang C. Wilson’s disease: a comprehensive review of the molecular mechanisms. International Journal of Molecular Sciences. 2015; 16(3): 6419–6431p.

Hepatitis. Hopkinsmedicine.org [Online]; 2023. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/hepatitis

Ashtanga Hridayam, edited by Pt Hari Sadashiv Sastri Paradakra, (chi.16/20-22). Varanasi: Chaukhambha Sanskrit Sansthan; Reprint 2016. 702p.

Bharat Bhaisajya Ratnakarby Rasa Vaidhya Nagindas Chaganlal Shah; part 3. Varanasi:Chaukhambha Sanskrit Sansthan; 1985. 540p.

Kumar N, Singh A. Phalatrikadi kwath-an Ayurvedic hepatoprotective drug. IJRPC. 2013; 3(3):591–594p.

Vanausadhi visheshank part 4 Aligarh: Jwala Ayurveda Bhavana; 2011. 210p.

Goraya GS, Ved DK. Medicinal Plants in India: An Assessment of their Demand and Supply.Dehradun; New Delhi: Indian Council of Forestry Research & Education; Neonatal Medicinal Plants Board, Ministry of AYUSH, Government of India; 2017.

Downloads

Published

2023-05-10

Issue

Vol. 12 No. 1 (2023)

Section

Case Study

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.